Allergan Inks Two More Deals With Molecular Partners On New Approach To Ophthalmic Conditions
This article was originally published in The Pink Sheet Daily
Allergan licenses a second novel product from Switzerland's Molecular Partners for ophthalmic indications and enters into a discovery alliance under which it has the option to license three further ophthalmic compounds.
You may also be interested in...
After raising $34 million from Britain’s stock market, the U.K. biotech now plans to develop its Affimer proteins as therapeutics as well as research reagents, to enable two complementary strands of business.
New therapeutic modalities can bring unexpected challenges in pricing, as uniQure and electroCore learn. Also, deal news from Celgene/OncoMed, Forest/Merck, Theraclone/PharmAthene, The Medicines Company/Rempex and Roche/Molecular Partners.
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.